GlassScriptPhysician profile
John G Latall
NPI 1487630364
$5,133.97
in general payments reported to CMS, 2019-2025
27 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $951 · 2021: $824 · 2022: $726 · 2023: $392 · 2024: $362 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,107.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $901.67 | 2019-2025 | Tezspire |
| Glaxosmithkline, LLC. | $708.07 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $413.19 | 2019-2024 | Dupixent |
| Csl Behring | $275.31 | 2019-2024 | Haegarda |
| Teva Pharmaceuticals USA, INC. | $188.43 | 2019-2022 | |
| Genzyme Corporation | $177.76 | 2021-2025 | |
| Optinose US, INC. | $166.02 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $156.26 | 2021-2024 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.58 | 2019-2023 | Spiriva Respimat |
| Pfizer INC. | $125.87 | 2019-2021 | |
| Hospira, INC. | $91.24 | 2019-2023 | |
| Genentech USA, INC. | $84.88 | 2019-2022 | |
| Grifols USA, LLC | $78.31 | 2019-2024 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $75.56 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $67.88 | 2021-2022 | |
| Shire North American Group INC | $64.25 | 2019 | |
| Amgen INC. | $60.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57.39 | 2019 | |
| Phadia US INC. | $35.66 | 2022-2024 | Immunocap |
| Leo Pharma INC. | $33.71 | 2023 | Adbry |
| Blueprint Medicines Corporation | $32.02 | 2023 | Ayvakit |
| Alk-Abello, INC | $28.94 | 2019 | |
| Kaleo, INC. | $22.77 | 2019 | |
| Abbvie INC. | $15.93 | 2022 | |
| Circassia INC. | $14.92 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Latall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.